Lijen Met is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:
• In patients inadequately controlled on their maximally tolerated dose of metformin alone.
• In combination with other medicinal products for the treatment of diabetes, including insulin, in patients inadequately controlled with metformin and these medicinal products.
In patients already being treated with the combination of linagliptin and metformin as separate tablets.
Sirolimus is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. It is recommended that Sirolimus be used initially in combination with ciclosporin microemulsion and corticosteroids for 2 to 3 months. Sirolimus may be continued as maintenance therapy with corticosteroids only if ciclosporin microemulsion can be progressively discontinued
Sirolimus is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. It is recommended that Sirolimus be used initially in combination with ciclosporin microemulsion and corticosteroids for 2 to 3 months. Sirolimus may be continued as maintenance therapy with corticosteroids only if ciclosporin microemulsion can be progressively discontinued
- Prophylaxis and treatment of angina pectoris.
- As an adjunctive treatment in the management of severe acute or chronic congestive cardiac failure.
Registration
Biological Drug
FluMist
Influenza vaccine (intranasal, live attenuated) (LAIV trivalent): Influenza Virus Type A H1N1, Influenza Virus Type A H3N2, Influenza Virus Type B (Victoria lineage)
Influenza vaccine (intranasal, live attenuated) (LAIV trivalent): Influenza Virus Type A H1N1, Influenza Virus Type A H3N2, Influenza Virus Type B (Victoria lineage)
الاستخدامات الطبية المعتمدة
FluMist is indicated for the prophylaxis of influenza in individuals from 2 to less than 18 years of age.
Airsupra is indicated for the as-needed treatment or prevention of bronchoconstriction and for the prevention of exacerbation in patients with asthma 18 years of age and older.
-Airsupra is also indicated for the prevention of exercise-induced bronchoconstriction in patients with asthma 18 years of age and older.
For adult patients with type 2 diabetes mellitus, Maysiglu is indicated to improve glycaemic control:
as monotherapy:
- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance as dual oral therapy in combination with:
- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control.
- a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance.
- a peroxisome proliferator-activated receptor gamma agonist (i.e. a thiazolidinedione) when use of a PPARγ agonist is appropriate and when diet and exercise plus the PPARγ agonist alone do not provide adequate glycaemic control.
as triple oral therapy in combination with:
- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.
Lijen Met is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:
• In patients inadequately controlled on their maximally tolerated dose of metformin alone.
• In combination with other medicinal products for the treatment of diabetes, including insulin, in patients inadequately controlled with metformin and these medicinal products.
In patients already being treated with the combination of linagliptin and metformin as separate tablets.
